Truqap/Faslodex Delays Time to Breast Cancer Progression, Next Therapy
Patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer tended to live longer until the time to second progression (PFS2; when the cancer worsens or spreads a second time) when Truqap (capivasertib) was added to Faslodex ( …